Shanghai Sinobioway Sunterra Biotechnology
Shanghai Sinobioway Sunterra Biotechnology specializes in advanced biotechnology, particularly in adoptive cellular therapies aimed at treating solid tumor malignancies. Established through a collaboration between Sinobioway Group, Sunterra Capital, and F1 Oncology, the company is dedicated to developing innovative CAB-CAR-T therapies. To facilitate its research and development efforts, SSSB operates Good Manufacturing Practice (GMP) cell processing facilities in Shanghai, which support clinical research in partnership with leading academic institutions.
EXUMA Biotech
Venture Round in 2018
Exuma Biotech is a clinical-stage biotechnology company focused on discovering and developing adoptive cellular therapies for solid tumors and hematological malignancies. Established in 2015 and headquartered in West Palm Beach, Florida, with additional locations in San Diego, California, Grand Cayman, and Shanghai, Exuma Biotech specializes in chimeric antigen receptor-T cell (CAR-T) therapy. The company aims to enhance the immune system's ability to combat various solid tumor malignancies, including renal cell carcinoma, soft tissue sarcoma, and gastric cancer. Through its logic-gated CAR-T platform, Exuma Biotech seeks to improve patient access to innovative cell and gene therapies. The company has formed strategic partnerships to advance its research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.